{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":22,"n_cols":5,"rows_kept":22,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[13,2,13,3],[14,2,14,3],[18,2,18,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910140760703321"]
[null,null,"Titolo",null,"Biotransformation and metabolite elucidation of xenobiotics [[electronic resource] /] / edited by Ala F. Nassar"]
[null,null,"Pubbl/distr/stampa",null,"Hoboken, N.J., : John Wiley & Sons, 2010"]
[null,null,"ISBN",null,"1-118-09777-7"]
[{"$nulls":4},"1-282-78289-4"]
[{"$nulls":4},"9786612782893"]
[{"$nulls":4},"0-470-89038-X"]
[{"$nulls":4},"0-470-89037-1"]
[null,null,"Descrizione fisica",null,"1 online resource (342 p.)"]
[null,null,"Disciplina",null,"615.9"]
[null,null,"Soggetti",null,"Xenobiotics - Metabolism"]
[{"$nulls":4},"Metabolites"]
[{"$nulls":4},"Biotransformation (Metabolism)"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"BIOTRANSFORMATION AND METABOLITE ELUCIDATION OF XENOBIOTICS; CONTENTS; PREFACE; CONTRIBUTORS; CHAPTER 1: HUMAN BIOTRANSFORMATION; CHAPTER 2: ANALYTICAL TOOLS AND APPROACHES FOR METABOLITE IDENTIFICATION IN DRUG METABOLISM; CHAPTER 3: TOOLS OF CHOICE FOR ACCELERATING METABOLITE IDENTIFICATION: MASS SPECTROMETRY TECHNOLOGY DRIVES METABOLITE IDENTIFICATION STUDIES FORWARD; CHAPTER 4: IMPROVING DRUG DESIGN: CONSIDERATIONS FOR THE STRUCTURAL MODIFICATION PROCESS"]
[{"$nulls":4},"CHAPTER 5: CASE STUDY: THE UNANTICIPATED LOSS OF N2 FROM NOVEL DNA ALKYLATING AGENT LAROMUSTINE BY COLLISION-INDUCED DISSOCIATION: NOVEL REARRANGEMENTSCHAPTER 6: CASE STUDY: IDENTIFICATION OF IN VITRO METABOLITE/DECOMPOSITION PRODUCTS OF THE NOVEL DNA ALKYLATING AGENT LAROMUSTINE; CHAPTER 7: STRATEGIES FOR THE DETECTION OF REACTIVE INTERMEDIATES IN DRUG DISCOVERY AND DEVELOPMENT; CHAPTER 8: SAFETY TESTING OF DRUG METABOLITES: MIST GUIDANCE IMPACT ON THE PRACTICE OF INDUSTRIAL DRUG METABOLISM; INDEX"]
[null,null,null,"Sommario/riassunto","The goal of this book is to improve the readers' knowledge of metabolite elucidation in drug metabolism by exposing them to in "]
[{"$nulls":4},"depth coverage of the biotransformation of xenobiotics, strategies for identifying and characterizing metabolites, FDA guidelines, and case studies on how to improve the decision-making process in structural modification of drug candidates to reduce toxicity. The book consists of 8 chapters; it first provides an introduction on biotransformation of xenobiotics, and then presents modern approaches and strategies for dealing with metabolite characterization, using tool"]